DANAHER CORP /DE/ is expected to release its Q3 2026 10-Q filing on October 19, 2026, before market open. Last quarter: Danaher's Q2 FY2026 revenue grew 5.5% YoY to $6.265B and net income rose 56.8% to $870M (EPS $1.23), driven by core sales growth and the absence of a prior-year $432M trade-name impairment, while the company closed its ~$9.8B acquisition of Masimo on June 10, 2026, adding significant long-term debt and goodwill.
EPS Estimate
$2.05
Revenue Estimate
$6.35B
Analyst consensus from Finnhub. Actual results posted within minutes of the SEC filing on the DHR page.
Drawn from management commentary in the Q2 2026 10-Q:
Total Q2 FY2026 revenue growth of 5.5% (GAAP) broke down into 3.0% core sales growth, 1.5% from acquisitions, and 1.0% from favorable currency. Core sales growth was led by the Life Sciences segment, with lesser contributions from Biotechnology and Diagnostics; core sales excluding respiratory testing rose 4.5%.
On June 10, 2026, Danaher acquired Masimo (2025 revenue ~$1.5B) for approximately $9.8 billion, or $180.00 per share net of cash acquired, financed with cash on hand plus new long-term debt and commercial paper; the deal is now part of the Diagnostics segment and preliminarily added ~$5.0B of goodwill.
Operating profit margin rose 520 basis points YoY to 18.0% in Q2 FY2026, primarily because Q2 FY2025 included a 730-bps impact from a Life Sciences trade-name impairment charge, partially offset by 175 bps of unfavorable Masimo-related fair value/transaction costs and 30 bps of dilutive effect from acquired businesses.
Revenue
$6.26B
++5.54% YoY
EPS (Basic)
$1.23
++59.74% YoY
Gross Margin
57.6%
-1.71% YoY
Operating Income
$1.13B
++48.29% YoY
Add DHR to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.